

Commentary

Open Access

Identification and management of adults with asthma prone to exacerbations: can we do better?

Neil C Thomson* and Rekha Chaudhuri

Address: Respiratory Medicine Section, Division of Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK

Email: Neil C Thomson* - n.c.thomson@clinmed.gla.ac.uk; Rekha Chaudhuri - rekha@yaho.com

* Corresponding author

Published: 30 December 2008

Received: 22 October 2008

BMC Pulmonary Medicine 2008, **8**:27 doi:10.1186/1471-2466-8-27

Accepted: 30 December 2008

This article is available from: <http://www.biomedcentral.com/1471-2466/8/27>

© 2008 Thomson and Chaudhuri; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Exacerbations are a major cause of morbidity in asthma and generate high health costs. Identification and management of adults with asthma who are prone to exacerbations is of considerable importance as by this means it should be possible to reduce the number of patients who currently experience inadequately controlled disease. Exacerbations occur most frequently in individuals with severe disease. Other risk factors include a history of a recent exacerbation, comorbidities such as a raised body mass index and psychological problems as well as current smoking and lower socio-economic status. A low FEV₁, particularly if combined with the additional information from questionnaires helps predict exacerbations. Despite the association between these risk factors and exacerbations it remains difficult to accurately predict in an individual patient with asthma whether they will go on to develop an exacerbation in the future. A major aim of international guidelines on the management of asthma is to prevent future risks of exacerbations, but some patients, particularly those with severe disease, respond poorly to current therapies and continue to experience recurrent exacerbations.

There is an unmet need for improved management strategies and drugs targeted at preventing asthma exacerbations. Monitoring induced sputum eosinophil cell counts is helpful in preventing exacerbations in some patient with severe asthma. Future developments are likely to include the identification of better biomarkers to predict exacerbations or the cause of exacerbations, augmentation of the immunological response to viruses at the time of the exacerbation, the use of telemonitoring in patients with severe asthma and the development of improved therapies targeted at reducing exacerbations.

Background

A major goal of international guidelines on the management of asthma [1] is to achieve control of current symptoms, lung function and reliever inhaler use and to prevent future risks of exacerbations and decline in lung function [2]. Despite the widespread dissemination of asthma guidelines many patients have inadequately controlled disease [3] and experience frequent exacerbations

of asthma [4,5]. Exacerbations are associated with an accelerated decline in lung function [6], generate high health costs [7] and are the main cause of mortality in asthma. The identification and appropriate management of adults with asthma who are prone to exacerbations is of considerable importance as by this means it should be possible to reduce the large number of patients who currently experience uncontrolled disease.

Definition and risk factors for exacerbations

Severe exacerbations, defined as the need for courses of high dose corticosteroids or hospitalization because of asthma, occur most commonly in patients with severe asthma. This group can experience exacerbation rates ranging from 1.5 [8] to over 4 exacerbations per year [4]. Information on previous asthma control, co-morbidities and demographic factors as well as physiological and inflammatory biomarkers may help identify some individuals prone to exacerbations. These factors are often associated with severe asthma. A history of a recent exacerbation within the last 3 months is associated with a considerably increased risk of a future exacerbation [relative risk (RR) 3.7] [9]. Several co-morbidities in patients with difficult-to-treat asthma are associated with recurrent exacerbations including severe nasal sinus disease [adjusted odds ratio (OR) 3.7], gastro-esophageal reflux (OR 4.9), recurrent respiratory infections (OR 6.9), psychological problems (OR 10.8) and obstructive sleep apnea (OR 3.4) [10]. Current smokers with asthma are more likely to experience exacerbations compared to non-smokers with asthma [11]. A raised body mass index is also a risk factor for exacerbations [RR 1.7 (1.2–2.3)] [9] and hospitalization because of asthma [12]. Hospital admission rates for asthma in the US are associated with lower socio-economic status and are higher in black and Hispanic patients with asthma compared to whites [13]. A low pre-bronchodilator FEV₁ of 60 to 80% of predicted gives a 2.4-fold increased risk of an exacerbation, which rises to 4.6-fold increased risk when the pre-bronchodilator FEV₁ is < 60% of predicted [14]. Addition of information gained from questionnaires, including a history of pet ownership, increases the likelihood of identifying exacerbations over the next 30 months to a medium risk (RR 3.0) or high risk (RR 11) [14].

The categorisation of patients with severe asthma by cluster analyses into different phenotypes termed early onset atopic asthma, obese non-eosinophilic asthma, early symptoms predominant asthma and inflammation predominant asthma found that exacerbation rates were high in each of the distinct categories, but that no sub-group was more prone to exacerbations [4]. Thus despite the association between known risk factors and exacerbations it remains difficult to accurately predict in an individual patient with asthma whether they will go on to develop an exacerbation in the future.

Management of patients prone to exacerbations

Several pharmacological and non-pharmacological management approaches are likely to be effective in preventing exacerbations. Current drugs therapies for asthma, particularly inhaled corticosteroids alone or in combination with long-acting beta₂ agonists, but also leukotriene modifiers and omalizumab all reduce the rate of asthma

exacerbations [1]. Different ways of using currently available medication may reduce exacerbation rates. The SMART approach, which involves using both budesonide and formoterol given as needed, reduces the frequency of severe exacerbations in patients receiving regular combination therapy [15], although the value of this approach in patients with severe asthma is less clear. The heterogeneity of the therapeutic response to corticosteroids and to other drug therapies for asthma means that some patients respond poorly to current treatments and continue to experience recurrent exacerbations [5], probably due to a combination of genetic and environmental factors [16] as well as poor adherence to drug therapy. Written individualized management plans, when combined with regular review, improve asthma control including reduced hospitalization and attendance at emergency rooms for exacerbations [17].

The effect of treating co-morbidities associated with severe asthma, targeting smokers with asthma to quit smoking [18] or patients with a high BMI to lose weight [19], may result in improvements in indices of current asthma control. Future studies are needed to assess whether these interventions reduce exacerbation rates. Avoidance of trigger factors such as allergens, non-steroidal anti-inflammatory agents or occupational agents in sensitive individuals, as well as exposure to environmental irritants such as passive smoke, is likely to prevent some exacerbations [1].

Can we do better?

Taken together, there is considerable evidence to indicate a need for improved methods both to identify adults with asthma who are prone to exacerbations and also to identify the early development and cause of an exacerbation. There is also a need for better management strategies and drugs targeted at treating and preventing exacerbations.

Monitoring biomarkers of airway inflammation may have a role in reducing exacerbation rates in selected patients. Treatment based on serial sputum eosinophil count measurements, prevents exacerbations in patients with severe asthma [20,21]. Serial exhaled nitric oxide measurements however, does not decrease exacerbation rates in 12–20 year olds [22] or in adults followed up for one year [23].

In future, it may be possible to use genetic markers to identify exacerbators. For example, in children and young adults with asthma the risk of asthma exacerbations is associated with filagrin null mutations [24] and IL-10 polymorphisms [25]. The complex and fluctuating interaction between environmental, immunological and mechanical factors on the risk of future exacerbations may require the use of sophisticated analytical methods to assess risk [26]. The majority of asthma exacerbations are caused by respiratory rhinovirus infections [27]. Recent

studies have demonstrated that patients with asthma are more susceptible to the clinical and inflammatory adverse effects of respiratory viruses due to augmented Th2 or impaired Th1 or IL-10 immunity [28]. These findings suggest that one approach in the future to the management of exacerbation may be through immunological augmentation with interferons at the time of the exacerbation [27] or by the use of specific anti-viral therapies. Telemonitoring of patients with severe asthma may be an advance that could identify worsening asthma control at an earlier stage, but evidence for this is still awaited. In the future, biological therapies, such as anti-IL13, current drugs, such as macrolides, or novel treatments, such as bronchial thermoplasty [29] may prove useful approaches in reducing exacerbations in some patients with severe asthma. Hopefully future research in asthma exacerbations will translate into improved levels of asthma control within the population.

References

- GINA Report, **Global Strategy for Asthma Management and Prevention** 2006 [<http://www.ginasthma.com/>].
- Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, et al.: **A new perspective on concepts of asthma severity and control.** *Eur Respir J* 2008, **32(3)**:545-554.
- Partridge M, Molen T van der, Myrseth S-E, Busse W: **Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study.** *BMC Pulm Med* 2006, **6(1)**:13.
- Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH: **Cluster Analysis and Clinical Asthma Phenotypes.** *Am J Respir Crit Care Med* 2008, **178(3)**:218-224.
- Pauwels RA, Lofdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A, The Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group: **Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma.** *N Engl J Med* 1997, **337(20)**:1405-1411.
- Bai TR, Vonk JM, Postma DS, Boezen HM: **Severe exacerbations predict excess lung function decline in asthma.** *Eur Respir J* 2007, **30(3)**:452-456.
- Lane S, Molina J, Plusa T: **An international observational prospective study to determine the Cost Of Asthma eXacerbations (COAX).** *Resp Med* 2006, **100(3)**:434-450.
- Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Della Cioppa G: **The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.** *Allergy* 2005, **60(3)**:302-308.
- Miller MK, Lee JH, Miller DP, Wenzel SE: **Recent asthma exacerbations: A key predictor of future exacerbations.** *Resp Med* 2007, **101(3)**:481-489.
- ten Brinke A, Sterk PJ, Masclee AAM, Spinhoven P, Schmidt JT, Zwinderman AH, Rabe KF, Bel EH: **Risk factors of frequent exacerbations in difficult-to-treat asthma.** *Eur Respir J* 2005, **26(5)**:812-818.
- Eisner MD, Iribarren C: **The influence of cigarette smoking on adult asthma outcomes.** *Nicotine Tob Res* 2007, **9(1)**:53-56.
- Rodrigo GJ, Plaza Y: **Body Mass Index and Response to Emergency Department Treatment In Adults With Severe Asthma Exacerbations: A Prospective Cohort Study.** *Chest* 2007, **132(5)**:1513-1519.
- Boudreaux ED, Emond SD, Clark S, Camargo CA Jr: **Acute Asthma Among Adults Presenting to the Emergency Department: The Role of Race/Ethnicity and Socioeconomic Status.** *Chest* 2003, **124(3)**:803-812.
- Osborne ML, Pedula KL, O'Hollaren M, Ettinger KM, Stibolt T, Buist AS, Vollmer WM: **Assessing Future Need for Acute Care in Adult Asthmatics: The Profile of Asthma Risk Study: A Prospective Health Maintenance Organization-Based Study.** *Chest* 2007, **132(4)**:1151-1161.
- Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Laloo UG: **Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.** *The Lancet* **368(9537)**:744-753.
- Spears M, Thomson NC: **Factors influencing individual variability to the therapeutic response to corticosteroids.** *Curr Resp Med Reviews* 2006, **2**:197-209.
- Gibson P, Powell H, Coughlan J, Wilson A, Abramson M, Haywood P, Bauman A, Hensley M, Walters E: **Self-management education and regular practitioner review for adults with asthma.** *Cochrane Database of Systematic Reviews* 2002.
- Chaudhuri R, Livingston E, McMahon AD, Lafferty J, Fraser I, Spears M, McSharry CP, Thomson NC: **Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with Asthma.** *Am J Respir Crit Care Med* 2006, **174(2)**:127-133.
- Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund E-L, Ylikahri M, Mustajoki P: **Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study.** *Br Med J* 2000, **320(7238)**:827-832.
- Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID: **Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.** *The Lancet* 2002, **360(9347)**:1715-1721.
- Jayaram L, Pizzichini MM, Cook RJ, Boulet L-P, Lemiere C, Pizzichini E, Cartier A, Hussack P, Goldsmith CH, Laviolette M, et al.: **Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations.** *Eur Respir J* 2006, **27(3)**:483-494.
- Szeffler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, Kattan M, Pongracic JA, Teach SJ, Bloomberg GR, et al.: **Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial.** *The Lancet* 2008, **372(9643)**:1065-1072.
- Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID: **The Use of Exhaled Nitric Oxide to Guide Asthma Management: A Randomized Controlled Trial.** *Am J Respir Crit Care Med* 2007, **176(3)**:231-237.
- Basu K, Palmer C, Lipworth B, Irwin McLean W, Terron-Kwiatkowski A, Zhao Y, Liao H, Smith F, Mitra A, Mukhopadhyay S: **Filaggrin null mutations are associated with increased asthma exacerbations in children and young adults.** *Allergy* 2008, **63(9)**:1211-1217.
- Hunninghake GM, Soto-Quirós ME, Lasky-Su J, Avila L, Ly NP, Liang C, Klanderman BJ, Raby BA, Gold DR, Weiss ST, et al.: **Dust mite exposure modifies the effect of functional IL10 polymorphisms on allergy and asthma exacerbations.** *J Allergy Clin Immunol* 2008, **122(1)**:93-98.
- Frey U, Suki B: **Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control.** *Lancet* 2008, **372(9643)**:1088-1099.
- Sykes A, Johnston SL: **Etiology of asthma exacerbations.** *J Allergy Clin Immunol* 2008, **122(4)**:685-688.
- Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebabdzic T, Contoli M, Sanderson G, Kon OM, Papi A, et al.: **Rhinovirus induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.** *PNAS* 2008, **0804181105**
- Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, Pavord ID, McCormack D, Chaudhuri R, et al.: **Asthma Control during the Year after Bronchial Thermoplasty.** *N Engl J Med* 2007, **356(13)**:1327-1337.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2466/8/27/prepub>